cas 19806-17-8|| where to buy 2,2'-(1,3-Phenylene)diacetic acid

Produktname:2,2'-(1,3-Phenylene)diacetic acid

IUPAC Name:2-[3-(carboxymethyl)phenyl]acetic acid

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM250974-25g	1-2 Weeks	ȡƎƦ
CM250974-100g	1-2 Weeks	ȺȐȺ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 19806-17-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:19806-17-8; Molekulare Formel:C10H10O4; Schmelzpunkt:-; SMILES-Code:O=C(O)CC1=CC=CC(CC(O)=O)=C1; Dichte:

: Katalognummer:CM250974; Molekulargewicht:194.19; Siedepunkt:401.6°C at 760 mmHg; Mdl-Nr.:MFCD00004341; Lagerung:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Sunobinop; Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function.
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.